In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...
Read More
In a nutshell This article reviewed which patients with mantle cell lymphoma benefitted most from a stem cell transplant. Some background Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin's lymphoma. It can be challenging to treat. There is no single standard treatment for patients with MCL. However, for young and fit patients, intensive...
Read More
In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...
Read More
In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read More
In a nutshell This trial is examining the effectiveness of CTX110, a treatment that modifies a patient’s own immune cells to treat relapsed or unresponsive non-Hodgkin lymphoma (NHL). The main outcome of this study is to see the number of patients that respond to treatment and side effects experienced. This study is recruiting in...
Read More
In a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...
Read More
In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read More
In a nutshell This study investigated the impact of high levels of calcium in the blood on the outcomes of patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that this condition is common patients with DLBCL and can lead to poorer outcomes. Some background About 25% of patients with cancer develop hypercalcemia (HC). This means...
Read More
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read More
In a nutshell This study examined if Y-90 (Zevalin) improved the effectiveness of chemotherapy for follicular lymphoma. The authors found that Y-90 improved the effectiveness of chemotherapy and was generally safe. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is usually treated with chemotherapy. BR...
Read More
In a nutshell This study looked at long-term outcomes for patients with follicular lymphoma after rituximab (Rituxan) maintenance therapy. This study concluded that rituximab maintenance helped improve long-term survival without disease progression compared to no treatment. Some background Follicular lymphoma (FL) is the second most common type of...
Read More
In a nutshell This study examined whether there is a link between the type of non-Hodgkin’s lymphoma (NHL) and the development of secondary cancer due to certain infections. The authors concluded that patients with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphoma (MZL) may be at risk for developing a second type of...
Read More
